GoodRx Announces New Affordability Programs for Menopause Hormone Therapies

GDRX 10.23.2024

Full Press ReleaseSEC FilingsOur GDRX Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Scott Wagner Joins GoodRx Board of Directors
  • 01.21.2025 - Steven Valiquette
  • 01.15.2025 - Wendy Barnes

Recent Filings

  • 01.22.2025 - 8-K Current report
  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.08.2025 - 3 Initial statement of beneficial ownership of securities
PDF Version

NewGoodRxresearch shows menopause medications have increased in price by over 50% over the last decade

SANTA MONICA, Calif.--(BUSINESS WIRE)--Oct. 23, 2024--Today,GoodRx(Nasdaq: GDRX), the leading prescription savings platform in theU.S., announced the availability ofnew affordability programs for menopause hormone therapiesby Pfizer. Through the reach and scale of theGoodRxplatform, these programs are broadening access and affordability of crucial medications for women.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20241023067340/en/

(Photo: Business Wire)

(Photo: Business Wire)

New research fromGoodRxshows menopause medications have increased in list price by 58% since 2014. And according to a recentstudy, people who’ve been diagnosed as menopausal spend 45% more on healthcare costs to treat their symptoms each year than those who are not menopausal. Similarly, women are often faced with a “pink tax,” which represents a significant inequality in healthcare where women pay more for their medical needs. That is whyGoodRxis working to make necessary menopause treatments more affordable and accessible for women who are faced with limited coverage and high out-of-pocket costs.

“Americans are paying more than ever for medications, a challenge that disproportionately affects women,” saidDorothy Gemmell, Chief Commercial Officer atGoodRx. “At GoodRx, we’re not just making strides towards affordability, but also championing the needs of women from perimenopause through menopause to improve their lives. We are committed to lowering prescription medications costs and shining a light on menopause – a complex condition that can impact a woman's physical, emotional, mental, and social well-being and having treatment options is critical.”

Now, eligible patients with a valid prescription can find low cash prices for brand-name menopause hormone therapies in the range of$99-$249at more than 70,000 pharmacies nationwide exclusively viaGoodRx.

For those looking for more affordable ways to access other menopause medications,GoodRxhas also created aSavings Guide for Popular Menopause Treatments.

“I’m thrilled to seeGoodRxtackle a major hurdle in women’s healthcare – the accessibility of menopause treatments,” said Dr.Lisa Larkin, Immediate Past President ofThe Menopause Society. “Menopause is a natural phase of a woman’s life that deserves attention and care, not something to be ignored or stigmatized. By reducing the cost barrier and spotlighting the importance of menopausal health, this initiative directly supports women’s health, their ability to enjoy their lives and encourages a broader dialogue about comprehensive care for all stages of a woman’s life. Efforts like this one are exactly what’s needed to improve health outcomes for women everywhere.”

GoodRxworks with over 150 brands across pharmaceutical manufacturers, medical device companies and OTC medicines to surface their savings and patient support programs directly with high-intent audiences via theGoodRxplatform. The company recently announced a partnership with ARS Pharmaceuticals to offerneffyat an exclusive low discounted cash price in retail pharmacies across theU.S.Similarly, the company launched an affordability program withBoehringer Ingelheimto provide its Humira® biosimilar (adalimumab) at a low cash price available exclusively onGoodRx.GoodRxnow has over 50 pharmaceutical brands offering cash price options for consumers integrated into theGoodRxplatform.

Further information can be found atwww.goodrx.com/go/menopause

AboutGoodRx

GoodRxis the leading prescription savings platform in theU.S.Trusted by more than 25 million consumers and 750,000 healthcare professionals annually,GoodRxprovides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011,GoodRxhas helped consumers save over$75 billionon the cost of their prescriptions.

GoodRxperiodically posts information that may be important to investors on its investor relations website athttps://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with theSecurities and Exchange Commission(the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; the expected benefits and value of our partnership with Pfizer and GoodRx’s other offerings; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year endedDecember 31, 2023, and our other filings with theSEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241023067340/en/

Press ContactGoodRxpress@goodrx.com

Source:GoodRx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com